GO:0036265 RNA (guanine-N7)-methylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036265 RNA (guanine-N7)-methylation is the biological process that adds a methyl group to the N7 atom of guanine in an RNA molecule, creating the cap-0 structure essential for mRNA stability and translation.
• The reaction is catalyzed by RNA guanine-7 methyltransferase enzymes, including RNMT in humans and orthologs in viruses such as coronavirus nsp14 and vesicular stomatitis virus L protein.
• N7-methylation of the RNA cap is critical for innate immune evasion, as unmethylated caps are recognized by host restriction factors like IFIT1.
• Coronavirus nsp14 is a bifunctional enzyme with both guanine-N7 methyltransferase and nucleoside-2'O methyltransferase activities, making it a prime antiviral target.
• Experimental approaches to study GO:0036265 include biochemical methyltransferase assays, structural biology, CRISPR knockout of RNMT or viral methyltransferases, and RNA-seq/Ribo-seq to assess cap-dependent translation.
• Dysregulation of RNA guanine-N7 methylation is linked to viral pathogenesis, cancer, and potential ribosomopathies, driving interest in therapeutic inhibitors.
Description
RNA (guanine-N7)-methylation (GO:0036265) is a fundamental biological process that modifies the 5' cap of RNA molecules by adding a methyl group to the N7 position of the guanine nucleotide. This modification is essential for the maturation, stability, and translation of messenger RNA and is conserved across eukaryotes and many viruses. The resulting N7-methylguanosine (m7G) cap is recognized by cap-binding proteins such as eIF4E, facilitating ribosome recruitment and protein synthesis. In recent years, the importance of this process has been highlighted by studies on viral pathogens, where N7-methylation of viral RNA caps enables evasion of innate immune detection. For researchers, understanding GO:0036265 provides insights into gene expression regulation, host-pathogen interactions, and potential therapeutic targets for infectious diseases and cancer.
RNA (guanine-N7)-methylation At A Glance
| GO ID | GO:0036265 |
|---|---|
| GO term | RNA (guanine-N7)-methylation |
| Ontology | biological_process |
| Synonym | None |
| Major function | Addition of a methyl group to the N7 atom of guanine in RNA, forming the m7G cap essential for RNA stability, translation, and immune evasion |
| Catalytic enzymes | RNA guanine-7 methyltransferases (e.g., RNMT in humans, nsp14 in coronaviruses, L protein in vesicular stomatitis virus) |
| Substrate | S-adenosylmethionine (SAM) as methyl donor; guanine nucleotide in RNA cap structure |
| Cellular location | Nucleus and cytoplasm, depending on organism and RNA type |
| Related processes | mRNA capping, cap-dependent translation, innate immune response |
What Is GO:0036265?
RNA (guanine-N7)-methylation is defined by the Gene Ontology as the addition of a methyl group to the N7 atom in the base portion of a guanine nucleotide residue in an RNA molecule. This enzymatic modification typically occurs on the 5' terminal guanosine of nascent RNA transcripts, converting the cap-0 structure (GpppN) into cap-1 (m7GpppN) and further methylated forms. The reaction is catalyzed by S-adenosylmethionine-dependent methyltransferases, which transfer a methyl group from SAM to the N7 position of guanine. This process is distinct from other RNA methylations such as 2'-O-methylation or N6-methyladenosine, and it is essential for cap function in translation and stability.
Why Is RNA (guanine-N7)-methylation Important in Cell Biology?
RNA (guanine-N7)-methylation is crucial because it generates the m7G cap that marks RNA as 'self' and enables efficient translation. Without this modification, RNAs are unstable, poorly translated, and can trigger innate immune responses. The process is also a key virulence factor for many viruses, including coronaviruses, which rely on their own methyltransferases to mimic host caps and evade detection. In humans, dysregulation of RNMT, the enzyme responsible for this modification, has been implicated in cancer and developmental disorders, making it a target for therapeutic intervention.
• Enables cap-dependent translation by recruiting eIF4E and the ribosome.
• Protects RNA from degradation by exonucleases and decapping enzymes.
• Prevents innate immune activation by avoiding recognition by IFIT1 and other sensors.
• Essential for viral replication and pathogenesis, as shown for coronaviruses and vesicular stomatitis virus.
• Regulates gene expression at the post-transcriptional level, influencing cell growth and differentiation.
• Dysregulation is linked to cancer, where altered cap methylation can drive oncogenic translation.
• Provides a target for antiviral drug development, with inhibitors of coronavirus nsp14 being actively pursued.
• Plays a role in RNA quality control and nuclear export.
• Involved in the life cycle of many RNA viruses, including flaviviruses and coronaviruses.
• Potential biomarker for diseases with defective RNA processing.
What Happens During RNA (guanine-N7)-methylation?
Recognition of the RNA cap substrate
In simple terms: The enzyme finds the end of the RNA that needs a protective cap.
The process begins with the recognition of the 5' terminal guanosine of the RNA, which is linked to the next nucleotide via a 5'-5' triphosphate bridge. This cap-0 structure is the substrate for the guanine-N7 methyltransferase. Structural studies of the human enzyme have revealed a conserved Rossmann-fold domain that binds the cap and positions the guanine for methylation. In coronaviruses, the nonstructural protein 14 (nsp14) acts as the N7-methyltransferase, and its crystal structure has been solved in complex with cap analogs and the methyl donor S-adenosylmethionine (SAM). The enzyme specifically recognizes the cap structure through a network of hydrogen bonds and aromatic stacking interactions.
Methyl transfer from SAM to guanine N7
In simple terms: A methyl group is transferred onto the guanine base, changing its chemical properties.
Once the cap is bound, the methyltransferase catalyzes the transfer of a methyl group from SAM to the N7 atom of the guanine. This reaction converts the cap-0 (GpppN) to cap-1 (m7GpppN). The mechanism involves nucleophilic attack by the N7 atom on the methyl group of SAM, facilitated by a general base in the active site. For the human RNMT, key catalytic residues include a conserved aspartate that activates the guanine N7 for methylation. In the vesicular stomatitis virus L protein, a similar mechanism is employed, and mutations in the methyltransferase domain abolish cap methylation and viral replication. The reaction is highly specific for the N7 position and does not methylate other positions on the guanine ring.
Conformational changes and product release
In simple terms: After the methyl group is added, the enzyme changes shape and releases the finished RNA.
Following methyl transfer, the enzyme undergoes conformational changes that reduce its affinity for the methylated cap, allowing product release. Structural and biochemical studies of the coronavirus nsp14 indicate that a conserved loop undergoes a disorder-to-order transition upon SAM binding, which positions the cap for catalysis and then facilitates release. In the human enzyme, product release is thought to be the rate-limiting step and may be regulated by interactions with other proteins such as RAM (RNMT-activating miniprotein). The released m7G-capped RNA is then competent for nuclear export and translation.
Coupling with other RNA processing events
In simple terms: This methylation happens together with other steps that make RNA ready to work.
In eukaryotes, guanine-N7 methylation occurs co-transcriptionally and is coupled with other capping steps, including the addition of the guanosine cap by RNA triphosphatase and guanylyltransferase, and 2'-O-methylation of the first nucleotide. In the non-segmented negative-strand RNA virus vesicular stomatitis virus, the L polymerase protein contains all the enzymatic activities required for cap formation, including the guanine-N7 methyltransferase, and these activities are coordinated within a single polypeptide. This coupling ensures that only properly capped and methylated RNAs are produced. In coronaviruses, nsp14 works in concert with nsp10, which stimulates its methyltransferase activity, and with nsp16 for 2'-O-methylation.
Key Genes Involved in GO:0036265 RNA (guanine-N7)-methylation
The following genes and proteins are central to RNA (guanine-N7)-methylation, as identified in the provided literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RNMT | Human RNA guanine-7 methyltransferase; catalyzes N7-methylation of the 5' cap | Target for cancer and antiviral research; structural studies |
| nsp14 (SARS-CoV-2) | Coronavirus N7-methyltransferase and proofreading exonuclease | Essential for viral immune evasion; antiviral target |
| nsp10 (SARS-CoV-2) | Cofactor that stimulates nsp14 methyltransferase activity | Part of the viral replication complex; potential drug target |
| nsp16 (SARS-CoV-2) | 2'-O-methyltransferase that acts after N7-methylation | Works with nsp14 to form cap-1; antiviral target |
| L protein (VSV) | Vesicular stomatitis virus polymerase with cap methyltransferase activity | Model for viral cap methylation; mutations affect virulence |
| RAM (RNMT-activating miniprotein) | Activates RNMT and regulates cap methylation | Modulates RNMT activity; potential regulatory node |
| eIF4E | Cap-binding protein that recognizes m7G cap | Links N7-methylation to translation initiation |
| IFIT1 | Innate immune sensor that binds unmethylated caps | Restricts viruses lacking N7-methylation |
| Giardia lamblia N7-MTase | Protozoan guanine-N7 methyltransferase | Model for evolutionary studies |
| Schizosaccharomyces pombe N7-MTase | Fungal guanine-N7 methyltransferase | Genetic model for cap methylation |
| PCTAIRE kinase | Potential regulator of RNMT | Implicated in RNMT phosphorylation |
| Importin-alpha | Nuclear import factor for RNMT | Regulates RNMT localization |
| Capping enzyme (human) | Guanylyltransferase that creates cap-0 | Upstream of N7-methylation |
| Vaccinia virus VP39 | Viral 2'-O-methyltransferase and cap methyltransferase | Model for viral cap methylation |
| Flavivirus NS5 | Viral methyltransferase with N7 and 2'-O activities | Antiviral target |
| Coronavirus nsp13 | Helicase involved in cap formation | Part of replication complex |
| Human RNMT-RAM complex | Active holoenzyme for cap methylation | Structural and functional studies |
| VSV L methyltransferase domain | Domain responsible for cap methylation | Mutations reduce virulence |
How Is RNA (guanine-N7)-methylation Regulated?
RNA (guanine-N7)-methylation is regulated at multiple levels. In humans, the activity of RNMT is stimulated by its binding partner RAM (RNMT-activating miniprotein), which forms a heterodimer and enhances catalytic efficiency. Phosphorylation of RNMT by cyclin-dependent kinases may also modulate its activity during the cell cycle. In coronaviruses, nsp14 methyltransferase activity is stimulated by nsp10, and this interaction is essential for efficient cap methylation and immune evasion. Additionally, the availability of S-adenosylmethionine (SAM) can influence methyltransferase activity, linking this process to cellular metabolism. Viral proteins such as the vesicular stomatitis virus L protein have intrinsic regulatory domains that coordinate cap methylation with transcription.
RNA (guanine-N7)-methylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| nsp14 (SARS-CoV-2) | COVID-19 pathogenesis; immune evasion | Point mutation of catalytic residues; viral replication assays |
| RNMT | Cancer; dysregulated translation | Knockout in cancer cell lines; Ribo-seq |
| IFIT1 | Innate immune restriction of viruses | Knockout mice; viral infection studies |
| L protein (VSV) | Viral encephalitis; cap methylation | Recombinant virus with methyltransferase mutations |
| nsp10/nsp16 | Coronavirus replication | Biochemical assays; inhibitor testing |
Viral pathogenesis and immune evasion
Many RNA viruses, including coronaviruses and flaviviruses, encode their own guanine-N7 methyltransferases to cap their RNA and evade host innate immunity. The N7-methylation of the viral cap prevents recognition by IFIT1, a sensor that binds unmethylated caps and inhibits translation. In coronaviruses, the nsp14 methyltransferase is essential for maximal virulence, and mutations that abolish N7-methylation attenuate the virus and trigger stronger immune responses. Similarly, the vesicular stomatitis virus L protein requires cap methylation for efficient replication and pathogenesis. These findings make viral methyltransferases attractive targets for antiviral drugs.
Cancer and dysregulated translation
In cancer, dysregulation of cap methylation can lead to increased translation of oncogenic mRNAs. RNMT, the human guanine-N7 methyltransferase, is overexpressed in some cancers and is associated with poor prognosis. The m7G cap is recognized by eIF4E, which is often upregulated in cancer, driving cap-dependent translation of growth factors and survival proteins. Targeting RNMT or its regulators may therefore offer a therapeutic strategy to inhibit oncogenic translation. However, direct evidence linking RNMT mutations to cancer is still emerging, and further studies are needed.
Ribosomopathies and developmental disorders
Defects in RNA modification pathways, including cap methylation, can impair ribosome biogenesis and function, leading to ribosomopathies. While direct links between GO:0036265 and specific ribosomopathies are not yet well established, the essential role of N7-methylation in mRNA translation suggests that its disruption could contribute to developmental defects. Studies in model organisms such as Schizosaccharomyces pombe have shown that loss of guanine-N7 methyltransferase affects growth and stress responses. Further research is needed to determine whether human mutations in RNMT or related genes cause developmental disorders.
From RNA (guanine-N7)-methylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RNMT affect global translation? | RNMT knockout cell lines; Ribo-seq and polysome profiling |
| Is nsp14 N7-methylation required for coronavirus virulence? | Recombinant virus with point mutations in nsp14; mouse infection |
| How does cap methylation regulate innate immunity? | IFIT1 knockout cells; viral infection with methyltransferase mutants |
| What is the structural basis of inhibitor binding to nsp14? | Crystallography of nsp14 with inhibitors; bi-substrate analogs |
| Does RNMT overexpression promote oncogenic translation? | RNMT overexpression in cancer cell lines; xenograft models |
| How is cap methylation coupled to transcription in VSV? | VSV L protein mutants; in vitro transcription assays |
How to Study the RNA (guanine-N7)-methylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Methyltransferase assay | Enzymatic activity of N7-methyltransferases | Inhibitor screening; enzyme kinetics |
| X-ray crystallography | Three-dimensional structure of enzyme-cap complexes | Mechanistic studies; drug design |
| Ribo-seq | Translation efficiency and ribosome occupancy | Assessing impact of N7-methylation on translation |
| RNA-seq | Gene expression changes | Global effects of methyltransferase knockout |
| CRISPR knockout screens | Genes required for viral replication or drug sensitivity | Host factor discovery |
| Immunoprecipitation of m7G cap | Identification of methylated RNAs | Mapping N7-methylated transcripts |
| In vitro transcription | Cap methylation by viral polymerases | Studying coupling with transcription |
| Mass spectrometry | Detection of methylated nucleotides | Quantification of m7G levels |
Biochemical methyltransferase assays
In vitro methyltransferase assays using recombinant enzymes and radiolabeled SAM are standard for measuring guanine-N7 methylation activity. These assays can use synthetic cap analogs or short RNA substrates and are often coupled with thin-layer chromatography or HPLC to detect m7G. For viral enzymes like nsp14, the assay can be adapted for high-throughput screening of inhibitors.
Structural biology (X-ray crystallography and cryo-EM)
Structural studies have provided detailed insights into the catalytic mechanism of guanine-N7 methyltransferases. Crystal structures of human RNMT and coronavirus nsp14 in complex with cap analogs and SAM have revealed the active site architecture and conformational changes during catalysis. Cryo-EM is increasingly used for large viral polymerase complexes containing methyltransferase domains.
RNA sequencing and Ribo-seq
RNA-seq can assess global changes in gene expression upon perturbation of N7-methylation, while Ribo-seq measures translation efficiency at codon resolution. These methods are powerful for studying the impact of RNMT knockout or viral methyltransferase mutations on cap-dependent translation. They can also reveal whether specific mRNAs are more sensitive to loss of N7-methylation.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to N7-methylation inhibitors or viral infection. For example, screens in cells infected with coronaviruses lacking N7-methylation can uncover host factors involved in immune sensing. These screens are valuable for discovering new components of the cap methylation pathway and host restriction factors.
How CRISPR Can Be Used to Study GO:0036265 RNA (guanine-N7)-methylation
Knockout
CRISPR knockout of RNMT or viral methyltransferase genes (e.g., nsp14) can abolish N7-methylation, leading to reduced translation and increased immune activation. For example, RNMT knockout cells show decreased cap-dependent translation and cell cycle arrest. In viruses, knockout of nsp14 is often lethal, but point mutations can be used to study partial loss of function.
Point Mutation
Point mutations in the catalytic residues of guanine-N7 methyltransferases (e.g., D203A in nsp14) can specifically abrogate methyltransferase activity without affecting other functions. Such mutants are valuable for dissecting the role of N7-methylation in viral pathogenesis and immune evasion. In human RNMT, mutations in the SAM-binding pocket can be introduced to study substrate specificity.
Knock-in
Knock-in of tagged RNMT or viral methyltransferases (e.g., FLAG-tagged nsp14) allows for affinity purification and proteomic analysis of interacting partners. Knock-in of reporter RNAs with defined cap structures can also be used to study the specificity of N7-methylation in vivo.
Overexpression
Overexpression of RNMT or viral methyltransferases can enhance cap methylation and promote translation of specific mRNAs. In cancer cells, RNMT overexpression increases oncogenic translation and proliferation. Overexpression of coronavirus nsp14 in cells can also be used to study its effects on host gene expression and immune signaling.
How EDITGENE Supports RNA (guanine-N7)-methylation Research
Researchers studying RNA (guanine-N7)-methylation-related genes often need to determine whether a candidate gene is causally involved in cap methylation, translation regulation, or viral pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of these pathways.
Contact EDITGENE today to design your custom CRISPR model for RNA (guanine-N7)-methylation research.
Frequently Asked Questions About RNA (guanine-N7)-methylation
What is RNA (guanine-N7)-methylation?
RNA (guanine-N7)-methylation is the biological process of adding a methyl group to the N7 position of guanine in an RNA molecule, forming the m7G cap that is essential for RNA stability, translation, and immune evasion.
What genes are involved in RNA (guanine-N7)-methylation?
Key genes include RNMT in humans, nsp14 in coronaviruses, and the L protein in vesicular stomatitis virus. Other related genes include nsp10, nsp16, and IFIT1.
Why is N7-methylation important for mRNA?
N7-methylation creates the m7G cap that recruits eIF4E for translation initiation and protects mRNA from degradation. It also prevents innate immune activation by IFIT1.
How does coronavirus nsp14 mediate immune evasion?
Coronavirus nsp14 methylates the viral RNA cap at the N7 position, mimicking host caps and avoiding recognition by IFIT1, thus evading innate immunity.
What diseases are associated with defects in RNA (guanine-N7)-methylation?
Defects are linked to viral pathogenesis (e.g., COVID-19), cancer through dysregulated translation, and potentially developmental disorders.
What methods are used to study RNA (guanine-N7)-methylation?
Common methods include methyltransferase assays, X-ray crystallography, Ribo-seq, RNA-seq, and CRISPR screens.
Can CRISPR be used to study RNA (guanine-N7)-methylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the function of methyltransferases and their regulators.
What is the role of RNMT in cancer?
RNMT overexpression can enhance cap-dependent translation of oncogenic mRNAs, promoting cancer cell growth. Targeting RNMT is a potential therapeutic strategy.
How does S-adenosylmethionine function in N7-methylation?
SAM serves as the methyl donor, transferring its methyl group to the N7 atom of guanine in a reaction catalyzed by guanine-N7 methyltransferases.
What is the difference between cap-0 and cap-1?
Cap-0 is the basic m7G cap formed by N7-methylation, while cap-1 has an additional 2'-O-methylation on the first nucleotide. Both modifications are important for immune evasion and translation.
Conclusion
RNA (guanine-N7)-methylation (GO:0036265) is a critical RNA modification that governs gene expression, translation, and host-pathogen interactions. The enzymes responsible, such as RNMT and viral nsp14, are attractive targets for therapeutic intervention in cancer and infectious diseases. Continued research using advanced CRISPR models and biochemical assays will further illuminate the mechanistic details and disease relevance of this essential process.
References
- 1. Pan R et al.. 2022. N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition.. mBio 13(1):e0366221 PMID: 35073761
- 2. Trotman JB et al.. 2017. RNA guanine-7 methyltransferase catalyzes the methylation of cytoplasmically recapped RNAs.. Nucleic Acids Res 45(18):10726-10739 PMID: 28981715
- 3. Ogino M et al.. 2024. The complete pathway for co-transcriptional mRNA maturation within a large protein of a non-segmented negative-strand RNA virus.. Nucleic Acids Res 52(16):9803-9820 PMID: 39077935
- 4. Georgiou I et al.. 2026. Crystallographic characterisation and development of bi-substrate inhibitors of coronavirus nsp14 methyltransferase.. RSC Med Chem PMID: 41502823
- 5. Fabrega C et al.. 2004. Structure and mechanism of mRNA cap (guanine-N7) methyltransferase.. Mol Cell 13(1):77-89 PMID: 14731396
- 6. Hausmann S et al.. 2007. Biochemical and genetic analysis of RNA cap guanine-N2 methyltransferases from Giardia lamblia and Schizosaccharomyces pombe.. Nucleic Acids Res 35(5):1411-20 PMID: 17284461
- 7. Decroly E et al.. 2008. Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity.. J Virol 82(16):8071-84 PMID: 18417574
- 8. Grdzelishvili VZ et al.. 2006. Identification of a new region in the vesicular stomatitis virus L polymerase protein which is essential for mRNA cap methylation.. Virology 350(2):394-405 PMID: 16537083
